AVANT DIAGNOSTICS, INC. (OTCMKTS:AVDX) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure.
On September 27, 2017, Avant Diagnostics, Inc. (the “Company”) issued a press release providing an update to shareholders, a copy of which is attached hereto as Exhibit99.1.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. The following exhibits are filed with this report:
Avant Diagnostics, Inc ExhibitEX-99.1 2 f8k092717ex99-1_avantdiag.htm PRESS RELEASE,…To view the full exhibit click
About AVANT DIAGNOSTICS, INC. (OTCMKTS:AVDX)
Avant Diagnostics, Inc., formerly American Liberty Petroleum Corp., is a medical diagnostic technology company. The Company focuses on the commercialization of a series of microarray-based diagnostic tests that provide early detection of cancers, neurodegenerative diseases, and other chronic and severe disease states. The Company specializes in large panel biomarker tests. The Company’s lead product is OvaDx, a non-invasive proteomics diagnostic screening test for the early detection of ovarian cancer. The Company’s primary activities are preparing sample specimens in order for OvaDx to obtain the United States Food and Drug Administration (FDA) approval. The Company’s product, OvaDx, is a microarray-based test that measures the activation of the immune system in blood samples in response to early-stage ovarian tumor cell development. It identifies stage I, II, III and IV disease markers in patient samples.